Correlates of SGLT-2-inhibitiors use among patients with atherosclerotic cardiovascular disease and type 2 diabetes mellitus: Insights from the department of veterans affairs

Mahmoud Al Rifai; Dhruv Mahtta; David J. Ramsey; Michelle T. Lee; Chayakrit Krittanawong; Sankar D. Navaneethan; L. Parker Gregg; Laura A. Petersen; Salim S. Virani

doi:10.1016/j.ahj.2021.12.006

Correlates of SGLT-2-inhibitiors use among patients with atherosclerotic cardiovascular disease and type 2 diabetes mellitus: Insights from the department of veterans affairs

Mahmoud Al Rifai
, Dhruv Mahtta
, David J. Ramsey
, Michelle T. Lee
, Chayakrit Krittanawong
, Sankar D. Navaneethan
, L. Parker Gregg
, Laura A. Petersen
, Salim S. Virani

Research output: Contribution to journal › Letter › peer-review

6 Citations (Scopus)

Abstract

This study using data from the Veterans Affairs (VA) administrative and clinical dataset examined determinants of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) use among patients with concomitant atherosclerotic cardiovascular disease (ASCVD) and diabetes mellitus. The aim of the present analysis was to identify barriers and facilitators associated with SGLT-2i in a real-world contemporary patient population in order to improve utilization of these guideline-directed agents.

Original language	English (US)
Pages (from-to)	160-162
Number of pages	3
Journal	American Heart Journal
Volume	248
DOIs	https://doi.org/10.1016/j.ahj.2021.12.006
Publication status	Published - Jun 2022
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.ahj.2021.12.006

Cite this

Al Rifai, M., Mahtta, D., Ramsey, D. J., Lee, M. T., Krittanawong, C., Navaneethan, S. D., Gregg, L. P., Petersen, L. A., & Virani, S. S. (2022). Correlates of SGLT-2-inhibitiors use among patients with atherosclerotic cardiovascular disease and type 2 diabetes mellitus: Insights from the department of veterans affairs. American Heart Journal, 248, 160-162. https://doi.org/10.1016/j.ahj.2021.12.006

@article{40ad52db3e494dbcbc74def576a58120,

title = "Correlates of SGLT-2-inhibitiors use among patients with atherosclerotic cardiovascular disease and type 2 diabetes mellitus: Insights from the department of veterans affairs",

abstract = "This study using data from the Veterans Affairs (VA) administrative and clinical dataset examined determinants of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) use among patients with concomitant atherosclerotic cardiovascular disease (ASCVD) and diabetes mellitus. The aim of the present analysis was to identify barriers and facilitators associated with SGLT-2i in a real-world contemporary patient population in order to improve utilization of these guideline-directed agents.",

author = "\{Al Rifai\}, Mahmoud and Dhruv Mahtta and Ramsey, \{David J.\} and Lee, \{Michelle T.\} and Chayakrit Krittanawong and Navaneethan, \{Sankar D.\} and Gregg, \{L. Parker\} and Petersen, \{Laura A.\} and Virani, \{Salim S.\}",

note = "Publisher Copyright: {\textcopyright} 2021",

year = "2022",

month = jun,

doi = "10.1016/j.ahj.2021.12.006",

language = "English (US)",

volume = "248",

pages = "160--162",

journal = "American Heart Journal",

issn = "0002-8703",

publisher = "Elsevier Inc.",

}

Al Rifai, M, Mahtta, D, Ramsey, DJ, Lee, MT, Krittanawong, C, Navaneethan, SD, Gregg, LP, Petersen, LA & Virani, SS 2022, 'Correlates of SGLT-2-inhibitiors use among patients with atherosclerotic cardiovascular disease and type 2 diabetes mellitus: Insights from the department of veterans affairs', American Heart Journal, vol. 248, pp. 160-162. https://doi.org/10.1016/j.ahj.2021.12.006

TY - JOUR

T1 - Correlates of SGLT-2-inhibitiors use among patients with atherosclerotic cardiovascular disease and type 2 diabetes mellitus

T2 - Insights from the department of veterans affairs

AU - Al Rifai, Mahmoud

AU - Mahtta, Dhruv

AU - Ramsey, David J.

AU - Lee, Michelle T.

AU - Krittanawong, Chayakrit

AU - Navaneethan, Sankar D.

AU - Gregg, L. Parker

AU - Petersen, Laura A.

AU - Virani, Salim S.

PY - 2022/6

Y1 - 2022/6

N2 - This study using data from the Veterans Affairs (VA) administrative and clinical dataset examined determinants of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) use among patients with concomitant atherosclerotic cardiovascular disease (ASCVD) and diabetes mellitus. The aim of the present analysis was to identify barriers and facilitators associated with SGLT-2i in a real-world contemporary patient population in order to improve utilization of these guideline-directed agents.

AB - This study using data from the Veterans Affairs (VA) administrative and clinical dataset examined determinants of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) use among patients with concomitant atherosclerotic cardiovascular disease (ASCVD) and diabetes mellitus. The aim of the present analysis was to identify barriers and facilitators associated with SGLT-2i in a real-world contemporary patient population in order to improve utilization of these guideline-directed agents.

UR - https://www.scopus.com/pages/publications/85126541154

U2 - 10.1016/j.ahj.2021.12.006

DO - 10.1016/j.ahj.2021.12.006

M3 - Letter

C2 - 34968441

AN - SCOPUS:85126541154

SN - 0002-8703

VL - 248

SP - 160

EP - 162

JO - American Heart Journal

JF - American Heart Journal

ER -

Correlates of SGLT-2-inhibitiors use among patients with atherosclerotic cardiovascular disease and type 2 diabetes mellitus: Insights from the department of veterans affairs

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this